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A model system of two related enzymes with conserved binding sites, namely N-myristoyltransferase from 
two different organisms, was studied to decipher the driving forces that lead to selective inhibition in such 
cases. Using a combination of computational and experimental tools, two different selectivity-determining 
features were identified. For some ligands, a change in side chain flexibility appears to be responsible for 
selective inhibition. Remarkably, this was observed for residues orienting their side chains away from the 
ligands. For other ligands, selectivity is caused by interfering with a water molecule that binds stronger to 
the off-target than to the target. Based on this finding, a virtual screen for selective compounds was 
conducted resulting in three hit compounds with the desired selectivity profile. This study delivers a 
guideline on how to assess selectivity-determining features in proteins with conserved binding sites and 
to translate this knowledge into the design of selective inhibitors. 
  
Introduction 
One major goal of drug design projects is to obtain high affinity ligands for a certain target while 
maintaining selectivity over potential off-targets and thereby reducing side effects. The most common and 
routinely applied strategies1 include the exploitation of differences in the overall shape of the binding 
site,2,3 electrostatic interaction patterns,4–7 displaceable water molecules8–11 or, if available, addressing an 
allosteric functional binding pocket.12 
However, the task of selective-ligand design becomes more challenging when facing a conserved binding-
site between target and off-target(s). Even though for such challenging scenarios selective inhibitors were 
reported, the underlying molecular mechanism for selectivity often remained unclear.13–17 In some of 
these cases, protein flexibility18,19 or explicit water molecules within the binding site8–11 of the enzymes 
appeared to be the main contributing factors. 
Here, we embarked to reveal the selectivity-determining features in proteins with conserved binding sites 
using N-myristoyltransferase (NMT) as a model system. NMT catalyzes the transfer of the C:14 saturated 
fatty acid mystistate to the N-terminal glycine residue of recognized proteins substrates. The enzyme has 
an ordered Bi-Bi reaction mechanism, binding first to myristoyl-CoA (MyrCoA) with the resulting 
conformational changes generating a peptide-binding site.20 Subsequent formation of a ternary 
MyrCoA:NMT-peptide complex leads to catalysis and product release. The recognized peptides are species 
dependent, but all possess an N-terminal glycine, which is activated during the reaction through 
deprotonation by the carboxylate group of the C-terminus of enzyme.21 NMT was shown to be essential 
for parasitic survival and virulence,22,23 and is a drug target for cancer, and a range of parasitic and viral 
diseases.24–33 In this study, we focused on NMT from the protozoan parasite Leishmania major (LmNMT) 
and its human homologue HsNMT1. Both enzymes share a sequence identity of 45.4 % but have highly 
conserved binding sites with only three residues differing (Figure 1). Further, chemically closely related 
selective and unselective inhibitors were reported and the binding modes of some of these compounds 
were elucidated using X-ray crystallography. 
Pyrazole sulfonamides constitute one large class of NMT inhibitors (e.g. 1 to 4 in Figure 2).34–36 They bind 
to LmNMT by forming hydrogen bonds with Ser330 from the pyrazole moiety which also forms π-π stacking 
interactions with Phe90 (Figure 1). The trimethylation of the pyrazole improves packing within that pocket 
by addressing Phe88 and Leu341. The sulfonamide moiety interacts water-mediated with His219 and the 
backbone of Asp396 and Gly397. A hydrophobic, aromatic linker stacks with Tyr217 while a basic center, 
which mimics the N-terminus of the substrates, interacts directly or via a water molecule with the 
catalytically active C-terminal Leu421.  
 
Figure 1: Superposition of binding sites of LmNMT-1 (yellow carbon atoms for protein and green for ligand, 
PDB code 2WSA) and HsNMT1-1 (blue carbon atoms for protein and white for ligand, PDB code 3IWE). For 
clarity, water molecules are only shown for LmNMT-1 (red spheres). Hydrogen-bonds are indicated as 
dashed lines. Residues differing between both NMTs are highlighted as sticks. Residues are labeled as 
LmNMT/HsNMT1. 
 
LmNMT - 1 
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Further compound classes, containing piperidinylindoles, aminoacylpyrrolidines and oxadiazole scaffolds, 
were also reported to inhibit NMT (e.g. 5 to 8 in Figure 2).37–39 All these compounds contain a basic center 
to interact with the C-terminus but bind to the open binding site conformation. This is characterized by a 
rotation of Tyr217 which gives access to a mainly hydrophobic pocket (Figure 3 a). Additionally, compound 
5 is lacking a functional group to form a hydrogen bond with Ser330.  
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Figure 2: Chemical structures of investigated NMT inhibitors. Protonation states for neutral pH was used 
for modelling. 
Several inhibitors selective for LmNMT over HsNMT1 were developed.34–40 In the reported crystal 
structures, the NMT inhibitors only form main chain interactions with the three non-conserved binding 
site residues (Figure 1). Hence, the reasons for selective inhibition remained unclear. For compound 5, 
which is about 108-fold selective for LmNMT over HsNMT1, it was initially hypothesized that the selectivity 
arises from rotation of Tyr217 in LmNMT which is required for binding (Figure 3 a).37,38 It was suggested 
that the corresponding rotation of Tyr296 in HsNMT1 could be unfavorable and thus cause selectivity.38 
However, recently the unselective L. donovani NMT (LdNMT) inhibitors 6a and 7 were reported (Figure 2; 
LdNMT and LmNMT share a sequence identity of 97.8% and inhibition data are comparable between the 
two enzymes.38). Compounds 6a and 7 bind in a similar orientation to NMT as compound 5, demonstrating 
that the orientation of Tyr217 alone cannot be the selectivity-determining feature (Figure 3).39  
Figure 3: Binding mode of compound 5 in comparison to other ligands. a) Superposition of LmNMT in 
complex with compound 1 (cyan carbon atoms of ligand and receptor, PDB code 2WSA) and compound 5 
(green ligand carbon atoms and yellow receptor carbon atoms, PDB code 4CGN). The binding modes of 
the two compounds differ in compound 5 lacking a hydrogen-bond acceptor to interact with Ser330 and 
Tyr217 only adopting the open conformation when 5 is bound. b) Superposition of the binding modes of 
the selective compound 5 (green carbon atoms, PDB code 4CGN) and the unselective compound 7 (cyan 
carbon atoms, PDB code 5A28) binding to LmNMT (yellow carbon atoms, for clarity, only shown from PDB 
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To obtain a more detailed understanding of the molecular driving forces that lead to selectivity in proteins 
with conserved binding sites, we studied ligand binding to LmNMT and HsNMT1 in detail. Using a 
combination of molecular dynamics simulations, isothermal titration calorimetry, enzyme inhibition assay, 
site-directed mutagenesis and X-ray crystallography the thermodynamics of ligand binding, protein 
dynamics, water network formation and their changes upon ligand binding were analyzed. This approach 
led to the identification of two different selectivity-determining features for the compounds described 
above. Based on these findings, a virtual screening for selective compounds was conducted resulting in 
three hit compounds with the desired selectivity profile. Together with these results, the implications of 
this study for the rational design of selective inhibitors in general are also discussed.  
Results 
Selectivity for wild type proteins 
First, we focused on the sulfonamides 1 – 4 and the indole derivative 5 (Figure 2). Different assays were 
previously used to determine inhibition constants.34,35,41 Thus, to obtain consistent values, the inhibition 
constants of the compounds were re-determined using a fluorescence assay. As reported earlier, 
compounds 1-3 inhibited strongly both enzymes with only minor selectivity, whereas compounds 4 and 5 
were selective for LmNMT with a selectivity index (SI) of 215 and 16, respectively (Table 1). 
Table 1: Inhibition constants and selectivity of NMT inhibitors 1-5. All measurements were performed at 
least in duplicates. Ki values as mean with standard error were calculated from IC50 and KM values using 
the Cheng-Prusoff equation.   
 Ki [nM]  
Compound LmNMT HsNMT1 Selectivity index (SI)a 
1 8.4 ± 1.3 31.6 ± 4.5 4 
2 1.4 ± 0.3 13.3 ± 2.8 9 
3 19.8 ± 2.5 96.4 ± 11.7 5 
4 2.0 ± 0.4 4.3 x102± 91 215 
5 9.8x102 ± 1.0x102 1.5x104 ± 4.4x103 16 
a SI was calculated as Ki (HsNMT)/Ki(LmNMT1) 
ITC experiments were performed to elucidate the thermodynamic binding profiles. The measurements 
confirmed selectivity of compound 4 and 5, albeit with an altered selectivity profile (SI of 8 for compound 
4 and 113 for compound 5, Figure 4 a and b, Table S 1 in supporting information). For all ligands, regardless 
of their SI, binding to LmNMT was clearly dominated by enthalpy, whereas for HsNMT1 enthalpic and 
entropic contributions were more balanced. 
Crystal structures of ligand 1 in complex with LmNMT and HsNMT1, as well as ligand 5 in complex with 
LmNMT were available in the protein databank (PDB42).35,38 Structure determination of the remaining 
structures was attempted in order to elucidate the binding modes of the ligands. Co-crystallization and 
soaking experiments of HsNMT1 with compound 5 were unsuccessful as no additional electron density for 
the ligand was observed within the binding site. For the selective ligand 4, crystal structures of the 
complexes with LmNMT and HsNMT1 with a resolution of 1.50 and 1.89 Å, respectively, were determined. 
In addition, for the unselective ligand 2 a structure in complex with HsNMT1 was determined at 2.05 Å 
resolution (Table S 2). In all available structures, the binding modes were conserved between both protein 










Figure 4: Thermodynamic profiles of compounds 1-5 binding to a) LmNMT and b) HsNMT based on 
ITC experiments. c) Thermodynamic profiles of compounds 1 and 4 binding to active-site mutants 
HsNMT1 N374H:L495M:Q496L and HsNMT1 L495M. ΔG°, ΔH° and -TΔS° are depicted as blue, green 




















































c)    
 Figure 5: Superposition of a) compound 4 binding to LmNMT (green ligand carbon atoms and yellow 
protein carbon atoms, PDB code 6EU5) and HsNMT1 (white ligand carbon atoms and blue protein 
carbon atoms, PDB code 6FZ5). b) Superposition of compounds 1 (white carbon atoms, PDB code 
3IWE), 2 (grey carbon atoms, PDB code 6FZ3) and 4 (light orange carbon atoms, PDB code 6FZ5) in 
complex with HsNMT1 (blue carbon atoms, residues only shown from HsNMT1-4 complex, residues 
covering the ligands are hidden for clear view). c) Compound 6 binding to LmNMT (green ligand 
carbon atoms and yellow protein carbon atoms, PDB code 6EWF) and HsNMT1 (white ligand carbon 
atoms and blue protein carbon atoms, PDB code 6FZ2). In a and c, residues are labeled as 
LmNMT/HsNMT1. 
LmNMT - 4 
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HsNMT1 – 1 / 2 / 4 
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Purely based on the interactions formed in the binding sites, the selectivity profile of the ligands could not 
be explained. Therefore, site-directed mutagenesis experiments combined with MD simulations were 
carried out to obtain a more detailed picture of the molecular reasons for selective inhibition by these 
compounds.  
Binding-site swap 
The binding sites of LmNMT and HsNMT1 are highly conserved. Within 5 Å around compound 1, the only 
difference are the change of His398, Met420 and Leu421 in LmNMT to Asn473, Leu495 and Gln496 in 
HsNMT1 (Figure 1). However, the ligands form no direct interactions with the side chain atoms of these 
residues. To elucidate the influence of these residues on selectivity, they were swapped with the 
corresponding residues in the orthologous protein to obtain LmNMT with an HsNMT1 binding site and vice 
versa. The inhibition profiles of the mutated proteins were subsequently determined. It turned out that 
LmNMT H398N:M420L:L421Q was no longer catalytically active while HsNMT1 N473H:L495M:Q496L was 
fully functional with a similar Km as the wild type (w. t., Supporting information Table S 3). For the latter 
enzyme, the Ki values of the unselective inhibitors 1-3 and the selective compound 5 were only slightly 
altered compared to w. t. HsNMT1 (Table 2). In contrast, the Ki of the previously selective compound 4 
decreased from 428.2 nM to 18.4 nM, compromising its selectivity.  
Table 2: Inhibition constants of compounds 1-5 against LmNMT and HsNMT1 active site mutants. All 
measurements were performed at least in duplicates. Ki values were calculated from IC50 and KM values 
using the Cheng-Prusoff equation. (n.d. = not determined due to inactive enzyme)  

















1 n.d. 20.1 ± 4.3 13.9 ± 3.2 n.d. 41.3 ± 8.6 4.0 ± 2.8 42.9 ± 16.4 
2 n.d. 6.2 ± 1.9 8.5 ± 3.6 n.d. 6.0 ± 3.2 0.9 ± 0.5 40.2 ± 9.2 
3 n.d. 25.8 ± 6.5 1.6 ± 0.8 n.d. 2.3 ± 0.8 19.1 ± 3.0 48.9 ± 20.1 
4 n.d. 18.4 ± 3.6 1.3 ± 0.3 n.d. 36.6 ± 5.0 18.0 ± 5.1 2.8x102 ± 
61.4 








To further narrow down the crucial amino acids for the changes in enzyme activity and inhibition, NMT 
variants with only one altered residue were generated and tested. The substitution M420L in LmNMT 
resulted in an inactive enzyme. Altering the corresponding residue in HsNMT1 (L495M) led to stronger 
inhibition by all investigated sulfonamides with the largest change observed for 4 while changing the C-
terminus (Q496L) had only a minor influence on the inhibition constant of these compounds (Table 2).  
MD simulations of the w. t. and mutated apo structures as well as the ligand-bound complexes were 
performed to elucidate the molecular reason for the altered selectivity profile. All simulations showed a 
high stability of the proteins without larger conformational changes within 50 ns (Table S 5). Careful 
inspection of the trajectories did not reveal any changes in the ligand interactions or the water network 
around the C-terminal residues that could explain the selectivity data. Therefore, we turned our attention 
to flexibility changes. For quantification of flexibility impairment, side-chain order parameters (S²) were 
calculated with S² = 1 indicating low and 0 high flexibility.43,44 Among all simulations, the most pronounced 
differences in S² for binding site residues between NMTs for both species were observed for the C-terminal 
residues (Leu421 in LmNMT and Gln496 in HsNMT1, Figure 6, Table S 6 and Table S 7). For HsNMT1, binding 
of the unselective compound 1 only slightly reduced the flexibility of the side chain of Gln496 compared 
to the apo structure (S²= 0.16 and 0.34 in ligand free system (values from two independent simulations) 
and S² = 0.45 in the complex with compound 1). In contrast, when binding the selective inhibitor 4, the 
flexibility of this side chain was reduced more drastically (S² = 0.75). However, for the parasitic enzyme, 
smaller changes in S² were observed for the C-terminal residue when binding this ligand. Similar results as 
for the parasitic enzyme were obtained from simulating the complex of compound 4 with the less selective 
mutated enzyme HsNMT1 L495M. In this case, in the unbound form, S² was determined to be 0.58 while 
it only increased to 0.63 S² in the compound 4-bound form and decreased to 0.20 when the unselective 
compound 1 was bound. Taken together, based on the MD simulations, in HsNMT1 the side chain of the 
C-terminal residue Gln496 is relatively flexible. This flexibility is most drastically impaired in the complex 
with the selective compound 4 (Figure 6). In contrast, the side chains of the C-terminal residues in LmNMT 
and the HsNMT1 L495M variant are already more rigid in the apo form and their flexibility is less effected 
by the bound ligands. Based on these results, one would expect that 4 binds less potently to HsNMT1 than 
to HsNMT1 L495M due to entropic reasons (Figure 4).  
To back-up the MD simulations, ITC measurements with the mutated proteins were performed (Figure 4 
c, Table S 4). For compound 1 binding to HsNMT1 N473H:L495M:Q496L the enthalpic contribution was 
increased whereas the entropic contribution was decreased compared to binding to the w. t. enzyme. In 
contrast, the gain in affinity (and loss of selectivity) of compound 4 binding to 
HsNMT1 N473H:L495M:Q496L, as well as HsNMT1 L495M was rather driven by an increase of entropy 
upon ligand binding, whereas the difference in affinity was more pronounced for the former protein.  
 
Figure 6: Side-chain order parameters of the C-terminal and preceding residues of LmNMT, HsNMT1 and 
HsNMT1 L495M. For unbound structures of LmNMT two simulations were run starting from PDB code 
3H5Z (blue bar) and 4CGP (green bar), as well as for HsNMT1 starting from PDB code 3IU1, chain B (blue 
bar) and 4C2Y, chain A (green bar). High values with a maximum of 1 indicate rigid side-chains, whereas 
low values represent high flexibility. 
 
To investigate why the selective compound 4 influences the flexibility of the C-terminus stronger than the 
unselective ligand, we analyzed the available crystal structures. Superposition of the binding modes of 1 
and 4 in NMT from both species revealed that the contact area between compound 4 and the C-terminus 
is larger than for compound 1 and the C-terminus (Figure 1, Figure 5a and b). Thus, the available space for 
movements of the C-terminus might become more restricted when 4 is bound compared to 1. 
Influence of Tyr217/296 on selectivity 
In contrast to compound 4, the affinity of compound 5 was not affected when swapping the binding sites 
of LmNMT and HsNMT1 (Table 1 and Table 2). Compared to the sulfonamides 1-4, compound 5 lacks a 
hydrogen-bond acceptor for Ser330/405 and the orientation of the hydrophobic linker moiety within the 
binding site differs (Figure 3 a). Furthermore, in the complex structure with compound 5, Tyr217 adopts 
an open conformation whereas Tyr217 is found in a closed conformation when binding the sulfonamides. 
Through the open conformation a sub-pocket is enlarged, which becomes partially occupied by the indole 
core of compound 5. Therefore, it was hypothesized earlier that adopting the open conformation is 
energetically more favorable in LmNMT compared to HsNMT1 and, thus, causes selectivity of compound 
5.38 However, recently non-selective LdNMT inhibitors, which are believed to have similar affinity to 
LmNMT and likewise bind to the open conformation, were found, defying this hypothesis.39 Our MD 
simulations support the latter findings. In two independent MD simulations of unbound HsNMT1, the open 
conformation was found in 93.2 and 72.3% of the time, respectively. In LmNMT the open conformation 
was not favored compared to HsNMT1 and occurred with similar frequency (81.2 and 75.8% of the time 
in two independent simulations of the unbound structure).  
Influence of water molecules on selectivity 
To identify the molecular reasons for selectivity of 5, we turned our attention to the water network formed 
with the amino acids lining the binding site. Crystal structure analysis revealed differences between 
LmNMT and HsNMT1 in close proximity to Tyr217/296. As mentioned above, adopting the open 
conformation of Tyr 217/296 enlarges a sub-pocket. This sub-pocket is occupied by several water 
molecules (Figure 7 a). The depth of this pocket is limited by two residues that differ between the NMTs 
(Met377 and Val378 in LmNMT; Ala452 and Val453 in HsNMT1, Figure 7).39 In this pocket, a specific water 
molecule, here referred to as W1 (corresponding for example to W629 in the PDB structure 3IU1, chain 
B), was found in crystal structures of unbound HsNMT1, but not of unbound LmNMT (the closest water 
molecules are 2.6 and 2.8 Å away from W1 in the parasitic enzyme). However, in crystal structures with 
bound sulfonamides, the inhibitors trap Tyr217/296 in the closed conformation and the water molecule 
W1 is found in LmNMT as well as HsNMT1 (Figure 7 b). When compound 5 is bound to LmNMT, this ligand 
occupies space close to the W1 hydration site. As a consequence, a water molecule is found at a slightly 
shifted position (Figure 7 c). Based on these observations, we hypothesized that W1 is causing selectivity 
of compound 5 for the following reason. W1 appears to be stronger bound to HsNMT1 than to LmNMT 
and as binding of 5 requires displacing this water molecule (or alternatively adopting a different binding 
mode in HsNMT1), 5 should bind stronger to LmNMT than to HsNMT1. As we could not obtain a crystal 
structure confirming the binding mode of 5 in HsNMT1, we turned to the MD trajectories to investigate 









Figure 7: Illustration of the sub-pocket containing the water molecule W1 close to Y296 in HsNMT1 a) 
Superposition of the sub-pocket containing W1 (PDB code 3IU1) with the positions of the water molecules 
found in this area in the LmNMT ligand-free crystal structure (yellow spheres, PDB code 3H5Z). The Fo-Fc 
electron density (countered at 3 σ) for the water molecules in the HsNMT1 structure (calculated with the 
water molecules in this area omitted from the structure), is also shown. b) Superposition of the sub-pocket 
close to Y217 (which corresponds to Y296 in HsNMT1) together with water molecules and the bound ligand 
1 (PDB code 2WSA) with the position of the water molecule W1 from HsNMT1 (blue sphere, PDB code 
3IU1). c) Superposition of the sub-pocket close to Y217 (which corresponds to Y296 in HsNMT1) together 
with water molecules and the bound ligand 5 (PDB code 4CGN) with the position of the water molecule 
W1 from HsNMT1 (blue sphere, PDB code 3IU1).   
The analysis of the MD simulations supported the hypothesis that W1 is crucial for selectivity of compound 
5. At the W1 position, water density maps were calculated from the simulations for all investigated binding 
sites. A water molecule was considered to be present if the density was higher than 0.07 as described 
previously.45 A water molecule was found in all simulations of HsNMT1 with and without the sulfonamides 
1 – 4 and in all simulations with these ligands bound to LmNMT, but not in simulations of apo LmNMT. 
Calculation of the free energy change of W1 relative to the bulk with the SPAM approach also indicated 
that W1 binding is more favored in HsNMT1 than in LmNMT.45 For complexes with the same ligands lower 
∆G values for that explicit hydration site were constantly found in HsNMT1 compared to LmNMT (Table S 
8). Additionally, ΔG of W1 slightly decreased in complexes with ligands compared to apo structures in 
HsNMT1. Further, in simulations of LmNMT-5, the binding mode of the ligand was stable and W1 was not 
present. In contrast, in two independent simulations of HsNMT1-5 (one starting from a docking pose 
generated in the absence of W1, the other one using a binding mode generated by a direct transfer of the 
binding mode of compound 5 in complex with LmNMT to HsNMT1), a different binding mode for the ligand 
was found. Throughout the trajectories, the W1 hydration site was predominantly occupied and the ligand 
binding mode was shifted by 2.1 ± 0.3 Å compared to LmNMT (calculated as heavy-atom RMSD of 
representative snapshots – defined as lowest protein backbone RMSD compared to the average 
coordinates throughout the trajectory - relative to binding mode from PDB code 4CGN, Figure 8). In this 
altered conformation, the secondary amine of the piperidine moiety is shifted by 2.9 ± 0.5 Å, abolishing 
hydrogen-bonding to the C-terminus. As it is known that a hydrogen-bond of a secondary amine with the 
C-terminus strongly contributes to binding affinity, the loss of this interaction might explain the reduced 
affinity of compound 5 for HsNMT1.34,38 
Figure 8: MD-derived binding modes of 5 binding to LmNMT and NMT1. For the LmNMT-5 complex, the 
structure with PDB code 4CGN was used as starting structure for the simulations (ligand carbon atoms in 
green, protein carbon atoms in yellow). For the HsNMT1-5 complexes, two different structures were used: 
1) a structure obtained from docking (ligand carbon atoms in white, protein carbon atoms in blue) or 2) a 
structure generated by transferring the binding mode from LmNMT to HsNMT1 (ligand carbon atoms in 
grey, protein carbon atoms in light blue). Residues are labeled as LmNMT/HsNMT1.  
 
We further investigated the hypothesis that displacement of W1 contributes to selective binding of 
compound 5 by modulating the stability of W1 through the alteration of amino acids in its surrounding 
and characterizing the binding properties of the resulting mutants. The goal was to create an environment 
of W1 in HsNMT1 that resembles that in LmNMT. To achieve this, first all residues in close proximity of W1 
were swapped with those found in LmNMT at these positions. To provide space for these, additional 
residues had to be exchanged with smaller residues as well. Finally, further residues were exchanged to 
exclude the effect of other non-conserved residues on ligand selectivity. In total, up to eight residues in 
HsNMT1 were altered (Figure 9). The binding site residues Asn473, Leu495 and Gln496 were included 
because of their proximity to the bound ligands and impact on the selectivity of compound 4. Further, 
Ala452 was changed to the corresponding Met and Leu453 to the corresponding Val as these residues 
LmNMT - 5 
HsNMT1 - 5 / 5 
define the depth of the sub-pocket to which W1 binds.39,46 The second shell residue Leu462 was changed 
to Val to avoid a clash with the side chain of the introduced Met452. In addition, Trp297 was exchanged 
to Phe, as it is adjacent to Tyr296, which can adopt an open or closed conformation and thus determines 
the width of the entry of the sub-pocket. Finally, based on structure analysis it appeared possible that 
Arg295 influences the closing of the binding site upon ligand or substrate binding through hydrogen bonds 
with backbone oxygen atoms of Gly470, Asp471 and Gly472 (Figure S 1) and thus contributes to the 
selectivity of compound 5 by stabilization of the open conformation. Therefore, this residue was swapped 
as well with the corresponding Asn. In total, 12 different HsNMT1 variants were generated, carrying up to 
8 altered residues.  
 
Figure 9: Residues in close proximity to W1 in HsNMT1 (blue carbon atoms, PDB code 3IU1) superimposed 
with corresponding residues in LmNMT (yellow carbon atoms, PDB code 3H5Z). Amino acids depicted as 
sticks were exchanged in HsNMT1 to the corresponding ones of LmNMT for the generation of HsNMT1-8x 




The Ki value of the unselective compound 1 was only slightly altered for HsNMT1 containing all eight 
swapped amino acids (HsNMT1 8x) compared to w. t. HsNMT1 (26.4 vs. 31.6 nM, Table 3 and Table 1). 
Similar results were also observed for HsNMT1 8x with the unselective compounds 2 and 3 (Ki of 4.4 nM 
vs. 13.3 nM and 22.3 vs. 96.4 nM, resp.). As HsNMT1-8x includes the substitution L495M, increased affinity 
for compound 4 compared to w. t. HsNMT1 was expected. This was indeed observed (79.4 nM vs. 430 
nM), however not to the same extend as seen for LmNMT (2 nM) or HsNMT1 L495M (18 nM). This indicates 
that the combination of multiple mutations can have opposing effects that partially cancel out each other. 
The most drastic change was observed for the selective compound 5. Its Ki value was reduced from 15.4 
µM to 0.97 µM which is very close to the Ki value for LmNMT inhibition (Ki = 0.98 µM). For none of the 
remaining HsNMT1 variants bearing a subset of these eight mutated residues a Ki below 5 µM was found 
for this compound. 
In the subsequently determined crystal structure of HsNMT1-8x (Table S 2) electron density for W1 was 
only found in one of four chains of the asymmetric unit. The resolution of this structure (1.94 Å), was 
slightly lower than that of the w. t. apo-HsNMT1 structure (1.42 Å). As water placement in electron density 
is resolution-dependent, we turned again to MD-simulations to investigate the water network further.47 
The simulations of HsNMT1-8x revealed a shift of the W1 coordinates by around 1 Å compared to the w. 
t. Collectively, the absence of the water molecule W1 in three out of four chains of HsNMT1-8x together 
with the shifted position in the MD simulations and the inhibition data obtained with the various HsNMT1 
variants strongly supports the hypothesis that W1 is crucial for selectivity of compound 5. 
  
Table 3: Inhibition constants of compounds 1 and 5 against HsNMT1 mutants. HsNMT1 6x contains 
W297F:A452M:L453V:L462V:L495M:Q496L and HsNMT1 8x contains R295Q: 
W297F:A452M:L453V:L462V:N473H:L495M:Q496L. All measurements were performed at least in 
duplicates. Ki values were calculated from IC50 and KM values using the Cheng-Prusoff equation.   
 Ki [nM] 
NMT 1 5 
HsNMT1 8x 26.4 ± 2.4 9.7 x102 ± 2.4 x102 
HsNMT1 A452M 79.2 ± 31.4 1.1x104± 3.3 x103 
HsNMT1 L453V 2.3x102 ± 2.0x102 > 1.5x104 
HsNMT1 A452M:L453V 3.0x102 ± 96.5 > 1.5x104 
HsNMT1 A452M:L453V:L462V 1.2x102 ± 40.5 1.0x104± 5.5x103 
HsNMT1 A452M:L453V:L495M 2.8x102 ± 1.5 x102 1.2x104± 6.1x103 
HsNMT1 6x 11.3 ± 10.5 8.7x103 ± 2.9x103 
HsNMT1 R295Q 69.1 ± 32.2 > 1.5x104 
HsNMT1 
R295Q:N473H:L495M:Q496L 
38.1 ± 16.9 5.6x103 ± 1.1 x103 
 
Profiling additional inhibitors 
The generated HsNMT1 variants allow profiling of further ligands to elucidate why they are selective.  
Interestingly, chloro-substituted derivatives of compound 6, e. g. 6a and 7, are non-selective for LdNMT 
over HsNMT1 while 6 is selective (Figure 2).39 Due to the almost identical sequence of LdNMT and LmNMT 
(97.8 %) and comparable IC50 values previously obtained for other inhibitors,38 a similar selectivity pattern 
for LmNMT over HsNMT1 was expected for these compounds. Further, 8 was also reported to be selective 
for LmNMT. 37–39 This data was confirmed by re-determining the inhibition profiles resulting in SI values of 
46.8, 4.5 and 10.5 for 6, 7 and 8, respectively (Table 4).  
To elucidate the reasons for selective inhibition, the compounds were subsequently tested against a 
selection of the generated HsNMT1 variants (Table 4). HsNMT1-8x was inhibited more strongly by all 
compounds compared to w. t. HsNMT1, resulting in a loss of selectivity for compounds 6 and 8 (SI 0.5 and 
0.1). When testing the compounds against HsNMT1 L495M and HsNMT1 N473H:L495M:Q496L, the affinity 
for 6 dropped again almost to the level of w. t. HsNMT1 thus restoring selectivity. In contrast, affinity for 
8 was still increased compared to w. t. HsNMT1 maintaining the loss of selectivity (SI 2 and 1.5). Thus, 6 
showed a similar inhibition profile in this panel as 5, whereas 8 behaved more like compound 4 (Table 1, 
Table 2, Table 3).  
The binding mode of compound 6 in complex with LmNMT and HsNMT1 was confirmed using X-ray 
crystallography (Table S 2, Figure 5 c). The oxadiazole ring was opened in the structure as observed before 
for 6a (PDB code 5A27). The ring opening is most likely caused by radiation damage during data collection 
(according to LC/MS data, 6a was intact when used for crystallization trials).39 Like 5, compound 6 binds to 
the open Try217/296 conformation. Whereas in HsNMT1-6 W1 is in the same position as in HsNMT1-apo, 
it is shifted by 0.5 Å in the LmNMT-6 structure. As a consequence compared to LmNMT-6, the ligand in 
HsNMT1 is slightly shifted (RMSD = 1.04 Å). MD simulations using intact structures of 6 also revealed a 
shifted binding mode (non-hydrogen RMSD = 1.3 Å for representative – closest to trajectory average 
coordinates - snapshots, Figure S 3 a). For unselective compound 6a similar binding modes were observed 
for both enzymes (RMSD = 0.91 Å, Figure S 3 b and c). Additionally, a W1 hydration site with a density of 
higher than 0.07 was found during simulations of both enzymes in complex with compound 6a, but only 
for HsNMT1 in complex with selective compound 6. Taken together this suggests that selectivity of 
compound 6 is, like for compound 5, caused by interference with water molecule W1. 
Table 4: Inhibition constants and SI (in parentheses) relative to LmNMT of compounds 6-8. All 
measurements were performed at least in duplicates. Ki values were calculated from IC50 and KM values 
using the Cheng-Prusoff equation.   
 Ki [nM] (SI) 
NMT 6 7 8 
LmNMT 70.8 ± 52.4 24.8 ± 2.3 2.8x10² ± 0.5x10² 
HsNMT1 3.3x10³ ± 2.3x10³ 
(47.8) 
1.1x10² ± 0.3x10² 
(4.5) 
2.9x10³ ± 1.3x10³ 
(10.5) 
HsNMT1 8x 33.0 ± 11.9 (0.5) 4.8 ± 1.4 (0.2) 29.2 ± 8.6 (0.1) 
HsNMT1 L495M 1.6x10³ ± 0.4x10³ 
(22.2) 
36.3 ± 6.2 (1.5) 5.5x10² ± 2.8x10² 
(2.0) 
HsNMT1 N473H:L495M:Q496L 2.1x10³ ± 1.5x10³ 
(29.7) 
42.5 ± 7.2 (1.7) 4.2x10² ± 0.4x10² 
(1.5) 
 
The compounds 4 and 8 showed a similar inhibition profile in the panel. Like 4, compound 8 places some 
atoms relatively close to the C-terminus (Figure 10). Thus, as observed for 4 (Figure 6), restricting the 
movements of the C-terminal residue in HsNMT1, but not in LmNMT or HsNMT1 L495M and HsNMT1 
N473H:L495M:Q496L is likely the reason for selective inhibition of 8. 
 
Figure 10: Binding mode of compound 8 (green carbon) in complex with LmNMT (yellow carbon, PDB code 
4CGL) superimposed with binding mode of compound 4 (cyan carbon atoms, PDB code 6EU5). 
 
Virtual Screening for selective LmNMT inhibitors 
A virtual screening for selective inhibitors was conducted based on the hypothesis that addressing the 
position of W1 in HsNMT1 leads to selective inhibitors. The core feature of the postulated pharmacophore 
was the requirement of a group to displace or interfere with W1 in the off-target HsNMT1 in a similar 
position as carbon C2 from compound 5 (grey sphere F1, Figure S 2). Further, interactions as observed for 
LmNMT - 8 / 4 
the inhibitors 1-7 were included to obtain reasonable binding affinity. Molecules passing the 
pharmacophore query were subsequently docked into the binding site and 6 compounds were selected 
for testing (Table S 9). 
An initial enzyme inhibition screen was performed with the purchased compounds against LmNMT and 
HsNMT1 in concentrations of 10, 100 and 500 µM. Compounds 9-11 revealed a concentration-dependent 
inhibition against LmNMT. Subsequently, the Ki values of these compounds against LmNMT were 
determined to be 19.6, 52.3 and 7.3 µM, respectively (Table 5). To check for unspecific binding, the 
compounds were tested against the unrelated NS2B/NS3 protease of dengue II virus. No inhibition was 
found at 100 µM suggesting no unspecific assay interference. Further, no inhibition at 100 µM and only 
low inhibition at 500 µM against HsNMT1 was observed, suggesting that the compounds are specific and 
selective for LmNMT. To further support the hypothesis that selectivity is caused by W1-interferrence, 
compounds 9-11 were also tested against HsNMT1-8x. This HsNMT1-variant was inhibited with Ki-values 
of 16.7 µM (cpd 9), 14.5 µM (cpd 10) and 23.8 µM (cpd 11), indicating the same selectivity mechanism for 
these compounds as found for 5 and 6.  
 
  
Table 5: Inhibition constants and percentage of inhibition at 500 µM of compounds 9-11 for LmNMT and 
HsNMT1. All measurements were performed at least in duplicates. Ki values were calculated from IC50 and 
KM values using the Cheng-Prusoff equation.   
 Ki [µM] (% inhibition at 500 µM)  




LmNMT 19.6 ±  3.4 (91 %) 52.3 ± 7.3 (90 %) 7.3 ± 3.0 (97 %) 
HsNMT1 >> 40 (59 %) > 200 (30 %) >> 40 (59 %) 
HsNMT1-8x 16.7 ± 4.1 (98 %) 14.5 ± 4.4 (93 %) 23.8 ± 7.5 (92 %) 
* The compound that was docked contained a 2-methylimidazoyl group whereas in-house NMR 
analysis revealed that the purchased compound contained a 4-methylimidazoyl group. 
 
Discussion and Conclusions 
A common goal in many drug discovery programs is to achieve high potency for the target and at the same 
time selectivity over off-targets. This is particularly challenging if the binding sites of the on- and off-targets 
are highly conserved. Here, we used LmNMT and its human homologue HsNMT1 as model systems for 
proteins with conserved binding sites to study selectivity-determining features in detail at the molecular 
level. Three key points stand out from this study: 1) For two different inhibitor series, two different 
selectivity-determining features were revealed. 2) Knowledge of these features could be exploited for the 
design of selective inhibitors. 3) The chosen approach can serve as guideline on how to assess selectivity 
determining features in proteins with conserved binding site and to translate this knowledge into the 
design of selective inhibitors. In the following, we elaborate on each of these points.  
Our strategy of combining X-ray crystallography, ITC, inhibition assay and MD simulations revealed two 
different selectivity-determining features within the inhibitor series under study. First, we revealed that 
also amino acids which orient their side chains away from the ligand, can contribute to selectivity. Second, 
we demonstrated that displacing or interfering with a water molecule from the HsNMT1 binding site 
contributes to selective inhibition of compounds from the indole and oxadiazole series. 
We started our investigations by changing the three non-conserved residues Asn473, Leu495 and Gln496 
in HsNMT1 to the corresponding residues in LmNMT and vice versa. As the side chains of these residues 
are oriented away from the bound ligands we did not expect a change in binding affinity for the 
investigated ligands binding to the modified pockets (Figure 1). In contrast to our expectations, the 
inhibition constants for the selective compound 4 dropped when binding to HsNMT1 
N473H:L495M:Q496L, reaching the level of binding to w. t. LmNMT and, thus, abolishing the selectivity, 
while the inhibition constants for the unselective compounds 1-3 were unaltered (Table 2). In fact, the 
exchange of L495M in HsNMT1 was enough to obtain an HsNMT1 variant which compound 4 inhibited 
with a similar potency as w. t. LmNMT. Both, ITC data and side chain order parameters calculated by MD 
simulations point in the direction that in this case entropic effects are causing selective inhibition (Figure 
4, Figure 6). Notably, it is not the exchanged residue for which the flexibility was altered but the 
neighboring one. The aminoacylpyrrolidine compound 8 shows a similar selectivity pattern with respect to 
w. t. NMTs and the variants generated in this study (Table 4). The inhibitors 4 and 8 place ligand atoms 
most closely to the C-terminus among the studied compounds and, thus, likely influence most drastically 
the flexibility of these residues in HsNMT1, leading to selectivity for LmNMT over HsNMT1 (Figure 10). We 
suggest therefore as one strategy for the design of selective LmNMT inhibitors to incorporate a bulky group 
into the ligands to restrict the flexibility of the C-terminus in HsNMT1. MD simulations to calculate the 
order parameters in the presence of potential ligands can be used to guide the selection of suitable groups. 
Further, the role of W1 as an alternative selectivity-determining feature was revealed. Interestingly, the 
affinity of the indole derivative 5 was not affected by swapping the three non-conserved binding site 
residues (Table 2). It was initially hypothesized that the selectivity of this compound is caused by binding 
to an open binding site conformation (as defined by the rotamers of Tyr217 and 296, respectively), which 
might be differently accessible in the investigated NMT variants.38 However, the subsequent identification 
of non-selective open-conformation-binding compounds (e. g. 6a and 7) and analysis of our MD 
simulations of NMT apo structures invalidated this hypothesis.39 Thus, we turned our attention to the 
water molecule W1 which is in close proximity to Tyr217/296 and likely influenced by binding of compound 
5 (Figure 9). In crystal structures and throughout MD simulation trajectories, at this position a water 
molecule was always found for HsNMT1 and for pyrazole sulfonamides bound to LmNMT. However, no 
water molecule was present for apo LmNMT and when the selective compound 5 is bound to LmNMT. 
Thus, we hypothesized that the water molecule W1 is more strongly bound to HsNMT1 than to LmNMT 
and that as a consequence ligands for which binding either requires displacement of W1 or adaption of an 
alternative binding mode in HsNMT1, have a higher binding affinity for LmNMT than for HsNMT1. This 
hypothesis was supported by generating HsNMT1-8x to which W1 bound more weakly based on evidence 
from crystal structure analysis and MD simulations and which in fact was more strongly inhibited by 
compound 5, eliminating its selectivity over LmNMT (Table 3). Compound 6 showed a similar inhibition 
pattern against NMT variants as 5, suggesting that W1 is also crucial for the selectivity of this ligand (Table 
4). MD simulations further suggested that for both ligands the binding mode in HsNMT1 is shifted 
compared to LmNMT, resulting in weaker interactions with the C-terminus, which likely explains their 
observed selectivity pattern (Figure 4 c, Figure 8 and Figure S 3 a). Interestingly, swapping only a subset of 
the 8 residues was not enough to abolish selectivity of 5 (Table 3). While the exchange R295Q alone is not 
able to alter the Ki value of 5 in the desired direction, this residue appears to become important when 
combined with other replacements as the exchange is contained in the two NMT variants with the most 
pronounced change in Ki values (HsNMT1-8x and R295Q:N473H:L495M:Q496L). Furthermore, the 
exchanges A452M and L453V, which define the depth of the sub-pocket, in combination with L495M as 
present in both HsNMT1-8x and HsNMT-6x, which also had a slightly reduced Ki for compound 5, seemed 
also to be important. Therefore, we hypothesize that a complex interplay between multiple residues is 
necessary to interfere with the affinity of W1. To further elucidate this interplay, more studies with 
additional NMT variants are required. We can only speculate about the biological role of W1. Due to its 
location close to the peptide binding grove, it might be involved in substrate specificity. However, 
additional experiments are necessary to investigate this further. 
Knowledge of one of the selectivity determining features was subsequently exploited for the design of 
LmNMT-selective compounds. A predictive virtual screening was performed using a pharmacophore 
model that included an expansion into the W1 binding groove as a selectivity marker (Figure S 2). This 
screening resulted in the identification of three novel compounds 9-11 with Ki values of 7.3 to 52.5 µM for 
LmNMT and selectivity over the human off-target (Table 5). To the best of our knowledge, this is the first 
example where selectivity of LmNMT over the human homologue could be achieved in a rational way. The 
activities of these compounds were restored against HsNMT1-8x, further supporting that W1 is crucial for 
selectivity. 
Finally, the procedure presented herein can be considered as a guideline for the determination of 
selectivity-determining features of proteins with conserved binding sites and to translate this knowledge 
into the design of selective ligands. Of particular importance in this study was the interplay between a 
range of experimental and computational methods that highlighted subtle differences in ligand binding 
which led to a better understanding of selectivity. While we chose to focus on enzymatic assays, ITC 
experiments, X-ray crystallography and MD simulations in other cases where selectivity might be caused 
by other factors, additional methods such as surface plasmon resonance to determine binding kinetics or 
NMR to experimentally determine protein and ligand dynamics might also be relevant. The critical role of 
water molecules for selective binding has already been revealed for other enzymes.1 However, unlike in 
many other studies, here computational analysis to predict the importance of certain water molecules for 
selectivity were underpinned with experimental data. More surprising in this study is probably the fact 
that selectivity can also arise from restricting side chain movements, even if the side chain is oriented away 
from the ligand. The protein variants generated in this study could also be used to decipher the selectivity-
determining features for structurally unrelated inhibitors. Such information can be very valuable for the 
design of ligands with improved affinity without the loss of selectivity. This study also showed that a 
complex interplay between several residues in and outside the binding site determines selectivity and 
more studies are needed to better understand this interplay. 
Experimental Section 
General Methods for synthesis and analytics 
1H and 13C NMR spectra were recorded on a Bruker Fourier 300 (300 MHz) spectrometer. Chemical shifts 
(δ) are expressed in ppm. Signal splitting patterns are described as singlet (s), broad singlet (bs), doublet 
(d), triplet (t), quartet (q), multiplet (m), or combinations thereof. 
Electron spray ionization (ESI) mass spectra were recorded on a Agilent 1100 series LC/MSD trap or 
Waters-ZQ2000 or Waters-Quattro-Micro, run in positive ion mode, using either methanol, 
methanol/water (95:5), or water/acetonitrile (1:1) and 0.1% formic acid as the mobile phase. The columns 
used were either a Waters Atlantis T3 C18 column, 150 mm × 4.6 mm, 3 µm particle size or Agilent 
Poroshell 120 EC-C18 column 150 mm x 2.1 mm, 4 µm particle size for analytics or a Waters Atlantis T3 
100 mm x 30 mm C18 column with 5 µM particle size for preparative separation. The following method 
was used for analytics:  water + 0.1% HCOOH (mobile phase A) and acetonitrile (mobile phase B) 95:5 to 
2:98 gradient over 7 min, and then held at for 2 min; flow rate 0.8 mL/min. 
The method for preparative separation was: A:B of 90:10 to 2:98 gradient over 8 min at a flow rate of 50 
mL/min with UV detection at 210 and 254 nm using a Waters 2996 Photodiode Array Detektor and ELSD 
detector Waters Micromass ZQ. 
All compounds had a measured purity of greater than 95% on this analytical HPLC-MS system (TIC and 
HPLC UV). HPLC retention times and M+ data are given below to substantiate the purity and integrity of 
the compounds. 1H and 13C NMR also confirmed compound identity and purity (with other organic 
components being absent). 
Thin layer chromatography (TLC) was carried out on Merck silica gel 60 F254 plates using UV light for 
visualization. TLC data are given as the Rf value with the corresponding eluent system specified in brackets. 
Column chromatography was performed using Merck silica gel (0.030-0.063 or 0.015-0.040 mm) 
prepacked columns using the mobile phases stated below. 
All reactions were carried out under dry and inert conditions unless otherwise stated. 
Synthesis and characterization of small molecules 
Inhibitors 1, 2, 3 and 5 were synthesized according to published procedures.34–36,38 Compound 4 was 
synthesized as described below. Compounds 6-8 were kindly provided by Prof. Ed Tate and co-workers 
from Imperial College, London. Compounds 9-14 (Supporting information) were purchased from 
Chembridge/hit2lead or WuXi Apptec/LabNetwork. Identity and purity of these compounds was 
confirmed by LC-MS analysis and NMR (only for compounds 9-11). 
2,6‐dichloro‐4‐[2‐(piperazin‐1‐yl)pyridin‐4‐yl]‐N‐(1,3,5‐trimethyl‐1H‐pyrazol‐4‐yl)benzene‐1‐sulfonamide (1) 
1H-NMR 400 MHz, Methanol-d4 ) δ 1.807 (3H, s), 2.043 (3H,s), 3.565 (2H, tbr), 3.627 (3H, s), 3.637 (2H, s.c.), 
3.652 (2H, s.c.), 3.712 (2H, tbr), 6.975 (1H, dd, J=5.3 Hz, J=1.4 Hz), 7.117 (1H, dbr, J=1.4 Hz), 7.892 (2H, s), 
8.12 (1H), 8.223 (1H, d, J=5.3 Hz);  
13C-NMR (400 MHz, Methanol) δ 163.35, 40.99, 46.56, 46.11, 47.30, 161.27, 149.89, 112.89, 147.22, 
106.94, 145.05, 130.89, 137.35, 137.24, 113.82, 140.41, 9.17, 36.48, 146.77, 10.75;  
C22H24Cl2N6O2S; Mass: 495.42 g/mol 
2,6‐dichloro‐4‐[2‐(4‐methylpiperazin‐1‐yl)pyridin‐4‐yl]‐N‐(1,3,5‐trimethyl‐1H‐pyrazol‐4‐yl)benzene‐1‐
sulfonamide (2) 
1H-NMR (400 MHz, Methanol-d4 ) δ 1.814 (3H, s), 2.048 (3H, s),  2.827 (3H, s), 3.225 (4H, tbr), 3.627 (3H, 
s), 3.893 (4H, tbr), 7.031 (1H, dd, J=5.3 Hz, J=1.1 Hz), 7.160 (1H, dbr, J=1.1 Hz), 7.890 (2H, s), 8.250 (2H, d, 
J=5.3 Hz); 
13C-NMR (400 MHz, Methanol) δ 44.29, 54.44, 44.03, 160.47, 149.95, 113.53, 147.27, 106.89, 144.76, 
130.84, 137.34, 137.28, 113.75, 140.21, 9.15, 36.45, 146.67, 10.70; 
C22H26Cl2N6O2S; Mass: 509.45 g/mol 
2,6‐dichloro‐N‐methyl‐4‐[3‐(piperazin‐1‐yl)propyl]‐N‐(1,3,5‐trimethyl‐1H‐pyrazol‐4‐yl)benzene‐1‐
sulfonamide (3)  
1H-NMR (400 MHz, Methanol-d4) δ  1.800 (3H, s), 2.002 (3H, s), 2.062 ( 2H, ddt, J=5.2 Hz, J=7.2 Hz, J=8.2 
Hz), 2.722 (2H, dd, J=7.2 Hz, J=8.2 Hz,), 3.213 (2H, dd, J=5.2 Hz, J=8.2 Hz), 3.381 (3H, s), 3.55 (2H, br), 3.56 
(2H, br),  3.636 (s), 7.466 (2H, s); 
13C-NMR (400 MHz, Methanol) δ 42.16, 49.83, 57.45, 25.79, 32.13, 148.36, 132.82, 137.48, 134.78, 40.32, 
118.35, 140.86, 9.39, 36.46, 146.76, 11.04; 
C22H29Cl2N5O2S; Mass: 474.45 g/mol 
 
 
Scheme 1: Synthesis of compound 4.  
Synthesis of compound 4 
Compound 4 was synthesized according to Scheme 1. 
4-bromo-2,6-dichloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide (4.1) 
706 mg of 4-bromo-2,6-dichlorobenzenesulfonylchloride (2,18 mmol) were added in small portions to a 
solution of 420 mg 1,3,5-trimethyl-1H-pyrazole (2.18 mmol) in 7.5 mL of pyridine and the mixture was 
stirred at room temperature for 24 h. Then diethyl ether was added to precipitate side products which 
were filtered off. The filtrate was distributed between dichloromethane and aqueous sodium hydrogen 
carbonate solution, the water layer was reextracted with dichloromethane, the combined organic layers 
were washed with sodium hydrogen carbonate solution and dried over magnesium sulfate and 
concentrated under reduced pressure. The product was triturated with diethyl ether and ultrasonic 
irradiation to form 610 mg of the product as slightly yellow solid (67 %). 
1H NMR (300 MHz, DMSO-d6) δ 9.71 (s, 1H), 7.97 (s, 2H), 3.56 (s, 3H), 1.91 (s, 3H), 1.71 (s, 3H). 
13C NMR (75 MHz, DMSO) δ 143.84, 137.16, 135.47, 135.39, 133.82, 125.87, 111.88, 39.52, 36.25, 10.49, 
8.59. 
4-bromo-2,6-dichloro-N-methyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzene-sulfonamide (4.2) 
To a solution of 455 mg 4.1 (1.1 mmol) in 4 mL DMF, 33 mg sodium hydride (as 55 mg 60% dispersion in 
parrafin, 1.4 mmol) were added in small portions at 0 °C. After gas evolution subsided, 82 μL methyl iodide 
(1,3 mmol) where added  and the reaction mixture was slowly warmed to room temperature and stirred 
overnight. Then the solvent was removed and the residue was distributed between 10 mL of 
dichloromethane and 20 mL of water. The organic layer was separated, dried over magnesium sulfate and 
concentrated under reduced pressure. The raw product was recrystallized from pentane to form 352 mg 
of a slightly yellow solid (0.82 mmol, 75 %). 
1H NMR (300 MHz, DMSO-d6) δ 7.99 (s, 1H), 3.58 (s, 2H), 3.30 (s, 2H), 1.91 (s, 2H), 1.74 (s, 1H). 
13C NMR (75 MHz, DMSO) δ 143.86, 137.76, 135.99, 134.38, 134.08, 126.41, 115.89, 39.86, 36.27, 10.85, 
8.83. 
Allyl acetate (4.3) 
2 g of allylic alcohol (34 mmol) and 4.5 g triethyl amine (44 mmol) in 20 mL of dichloromethane under 
argon were cooled in an ice bath. Then a solution of 3.5 g acetyl chloride (45 mmol) in 10 ml 
dichloromethane was added dropwise with intense cooling. The mixture was refluxed for 1 h and then 
stirred at room temperature for 12 h. Then the reaction mixture was washed with diluted sodium hydrogen 
carbonate solution, followed by concentrated sodium hydrogen carbonate solution and water. The organic 
layer was dried over magnesium sulfate and evaporated to yield 1.4 g of the product (14 mmol, 41 %) as 
yellow oil, which had sufficient purity for subsequent reactions. 
1H NMR (300 MHz, Chloroform-d) δ 5.91 (ddt, J = 17.1, 10.4, 5.8 Hz, 1H), 5.45 – 5.13 (m, 3H), 4.56 (dt, J = 
5.7, 1.3 Hz, 3H), 2.07 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 170.82, 132.29, 118.34, 65.27, 21.03. 
3-(3,5-dichloro-4-(N-methyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl)phenyl)-propyl acetate (4.4) 
100 mg allyl acetate 4.3 (1 mmol) and 244 mg dimeric 9-borabicyclo[3.3.1]nonane (2 mmol 9BBN) were 
dissolved in 2 mL THF and heated under argon to 65 °C for 1 h. After cooling to room temperature 428 mg 
4.2 (1 mmol), 50 mg of tetrakis(triphenylphosphin)palladium(0) (0,04 mmol) and 1 ml water were added 
and the mixture was heated to 60 °C with microwave irradiation. Afterwards, the reaction mixture was 
concentrated under reduced pressure and directly subjected to column chromatography (flash column, 
eluent: cyclohexane : ethyl acetate [1:1]) to yield the product, still containing the Pd-catalyst as a pale oil, 
containing 190 mg product (0,42 mmol, 42 %, determined via NMR). 
1H NMR (300 MHz, Chloroform-d) δ 7.20 (s, 2H), 4.02 (t, J = 6.3 Hz, 2H), 3.62 (s, 3H), 3.34 (s, 3H), 2.61 (t, J 
= 7.7 Hz, 2H), 2.02 (d, J = 4.4 Hz, 6H), 1.89 (p, J = 6.9 Hz, 2H), 1.75 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 170.91, 147.03, 145.24, 138.56, 133.30, 133.14, 131.93, 131.77, 131.31, 117.00, 
63.08, 39.95, 36.47, 31.21, 29.21, 20.90, 11.00, 9.48. 
2,6-dichloro-4-(3-hydroxypropyl)-N-methyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide (4.5) 
240 mg 4.4, containing 190 mg mg propyl acetate compound (0,42 mmol) were stirred in 5 mL methanol 
containing 400 mg sodium methanolate overnight. The next day, 50 mg of sodium hydroxide were added 
and the mixture was stirred for further 2 h. Then the mixture was neutralized with diluted hydrochloric 
acid, concentrated under reduced pressure and mixed with 20 ml dichloromethane and aqueous sodium 
hydrogen carbonate solution. The organic layer was separated and the aqueous layer was extracted with 
dichloromethane two times. All organic layers were concentrated under reduced pressure and purified by 
column chromatography (flash column, gradient: cyclohexane : ethyl acetate [1:2] → pure ethyl acetate) 
to yield 123 mg of the product as pale oil (0,30 mmol, 71 %). 
1H NMR (300 MHz, Chloroform-d) δ 7.19 (s, 2H), 3.58 (s, 3H), 3.54 (t, J = 6.2 Hz, 2H), 3.31 (s, 3H), 2.66 – 
2.57 (m, 2H), 1.99 (s, 3H), 1.85 – 1.73 (m, 2H), 1.72 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 148.13, 145.30, 138.63, 135.88, 132.80, 131.42, 116.99, 60.79, 39.89, 36.35, 
32.98, 31.00, 10.89, 9.39. 
3-(3,5-dichloro-4-(N-methyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl)phenyl)-propyl methanesulfonate 
(4.6) 
123 mg 4.5 (0.3 mmol, 1 äq.) in 5 mL dichloromethane were mixed with 61 mg (84 µL, 0,6 mmol, 2 äq.) at 
0 °C. Under further cooling with an ice bath, 51 mg of methyl sulfonyl chloride (35 µL, 0,45 mmol, 1.5 äq.) 
in 1 mL dichloromethane were added and the mixture was stirred at room temperature for two days. After 
this time, 20 ml dichloromethane were added and this mixture was washed with water three times, dried 
over magnesium sulfate and concentrated under reduced pressure. The raw product was assumed to be 
formed quantitively and was used for the subsequent reaction without further analysis or purification. 
(R)-2,6-dichloro-4-(3-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)propyl)-N-methyl-N-(1,3,5-trimethyl-1H-
pyrazol-4-yl)benzenesulfonamide (4) 
Presumably 145 mg of the previous formed 4.6 (0.3 mmol, 1 äq.) was dissolved in 5 mL acetonitrile and 
mixed with 90 mg triethyl amine (124 µL, 0.9 mmol) prior the addition of 70 mg (R)-octahydropyrrolo[1,2-
a]pyrazine (0.56 mmol, 1.9 äq.). The mixture was refluxed for 4.5 h, concentrated under reduced pressure 
and preliminary purified by column chromatography (flash column, gradient: isopropanole : chloroform 
[1:1]) to yield 120 mg of the product as brownish resin, which was further purified by HPLC to yield 85 mg 
of highly pure title compound 4 (0.17 mmol, 57 %). 
Rf = 0.35 (methanol + 1% NH3) 
Mass: 513.17 (calculated), found: 514.6 (MS ES+) 
1H NMR (300 MHz, Acetone-d6) δ 7.46 (s, 2H), 3.62 (s, 3H), 3.38 (d, J = 1.8 Hz, 3H), 3.05 – 2.85 (m, 3H), 2.81 
– 2.65 (m, 3H), 2.39 – 2.28 (m, 2H), 2.26 – 2.09 (m, 1H), 2.08 – 2.03 (m, 3H), 2.00 (s, 4H), 1.90 – 1.79 (m, 
2H), 1.77 (s, 4H), 1.75 – 1.62 (m, 2H). 
13C NMR (75 MHz, Acetone) δ 150.15, 145.42, 138.81, 136.48, 132.80, 63.51, 58.66, 57.40, 54.02, 53.36, 
52.40, 40.42, 36.81, 32.86, 28.51, 28.45, 22.21, 11.59, 9.58. 
2‐(4‐fluorophenyl)‐N‐[3‐(piperidin‐4‐yl)‐1H‐indol‐5‐yl]acetamide (5) 
1H-NMR (300 MHz, DMSO-d6) δ 9.07eq (1Hax, d, J=10 Hz), 8.87ax (1Heq,1Hax, dt, J=10 Hz, J=8.8 Hz), 3.30eq (1Hax, 
dbr, J=12.3 Hz,), 3.04ax (1Heq, 2Hax, “q”br, J~10 Hz, J=12.3 Hz), 2.07eq (1Hax, dm, J=13.5 Hz), 1.84ax (1H, 
2Heq,1Hax,  dq, J~13 Hz, J=3.6 Hz), 3.03ax (1Hax,1Heq, tt, J=13,  J<3,), 7.09 (1H, d, J=1.8 Hz), 10.87 (1H, d, J=1.8 
Hz), 7.27 (1H, d, J=8.7), 7.13 (1H, dd, J=8.7 Hz, J=1.7 Hz), 7.95 (1H, d, J=1.7 Hz), 10.14, 3.64, 7.39 (2H, dd 
s.c., J=8.8 Hz, J=5.5 Hz, 3JCF=7.8 Hz), 7.15 (2H, dd s.c., J=8.8 Hz, J=9.2 Hz, 2JCF=20.9 Hz);  
13C-NMR (300 MHz, DMSO-d6) δ 43.41, 29.14, 30.74, 117.99, 121.48, 133.20, 109.35, 115.15, 130.74, 
111.39, 125.63, 168.39, 42.22, 132.14, 130.93, 114.91, 161.06; 
C21H22FN3O; Mass: 351.42 g/mol 
Analytic data of compounds 9-14 
Compound 9, mass: 379.48 (calculated), 379.4 (found) 
Compound 10, mass: 357.48 (calculated), 357.4 (found) 
Compound 11, mass: 379.48 (calculated), 379.4 (found) 
Compound 12, mass: 396.46 (calculated), 396.5 (found) 
Compound 13, mass: 379.48 (calculated), 379.4 (found)  
Compound 14, mass: 366.44 (calculated), 366.4 (found) 
Protein purification 
Plasmids coding for LmNMT (11-421) and HsNMT1 (115-496) with an N-terminal hexahistidine tag and a 
TEV protease cleavage site were purchased from addgene. The gene coding for HsNMT1 
R295Q:W297F:A452M:L453V:L462V:N473H:L495M:Q496L was synthesized by GenScript and cloned into 
a pET-15b vector. All other mutations were generated using the Quick Change (Multi-)Site directed 
Mutagenesis kits (QIAGEN).  
NMT proteins were expressed and purified as described previously.34,35 Briefly, the enzymes were 
expressed in E.coli Rosetta2 cells using TB medium and IPTG induction. Harvested cells were resuspended 
in 50 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol and 5 mM imidazole. Cells were lysed by sonication 
after addition of lysozyme, DNAse I and a protease inhibitor cocktail tablet. The cleared lysate was loaded 
onto a 5mL HisTrap HP column (GE Healthcare) using an ÄKTA purifier or ÄKTA pure system and eluted by 
a 5-250 mM imidazole gradient. Fractions corresponding to NMT were pooled and concentrated. Identity 
and purity were checked by SDS-PAGE gel with Coomassie blue staining. 
Crystallization 
For crystallization proteins were rebuffered into 50 mM sodium phosphate buffer pH 7.5 and concentrated 
to 10 mg/mL for LmNMT and 5-8 mg/mL for HsNMT1, respectively. NMTs were incubated with 1mM 
MyrCoA and 0.5-1 mM inhibitor on ice for 1h. Crystallization was performed similarly as done recently48 
using the hanging drop vapor diffusion method with 22-24% PEG4000, 5mM NiCl2, 100 mM sodium citrate 
and 2.5% glycerol at pH 4.5 or 25% MPEG2000, 200 mM KBr, 100 mM sodium citrate, 5% glycerol at pH 
4.5 for HsNMT1 and 25% PEG1500, 200 mM NaCl, 100 mM sodium cacodylate at pH 5.6 for LmNMT.34 
X-ray data collection 
For HsNMT1-6, the X-ray diffraction data were collected in-house at the Johannes Gutenberg University 
on the generator Bruker AXS Microstar-H with Mar Scanner 345 mm image plate detector. Crystals of 
HsNMT1-2 and HsNMT1-4 were measured on the synchrotron beamline ID29 at the European Synchrotron 
Radiation Facility (ESRF) in Grenoble with a Pilatus 6M (Decritis LTD) detector, and data for LmNMT-4, 
LmNMT-6 and HsNMT1-8x were collected on beamline ID30A-1 / MASSIF-149,50 with a Pilatus3 2M (Decritis 
LTD) detector. 
Structure solution and refinement 
For HsNMT1-2 data were processed using XDS51 and SCALA52 and for HsNMT1-4 using Mosflm53 and SCALA. 
For HsNMT1-6, xia2 with XDS and SCALA was used for processing, whereas autoPROC54 with XDS/XSCALE 
was utilized for LmNMT-4, LmNMT-6 and HsNMT1-8x. The scaled data were phased with the PHASER 
molecular replacement technique using HsNMT1-4 (for HsNMT1-2 and -6), 3IWE (for HsNMT1-4), 3H5Z 
(for LmNMT-4 and LmNMT-6) or 4C2Y (for HsNMT1-8x) as search model.55,56 Automated refinement for 
HsNMT1-2, -4, and -6 was carried out with the PDBredo server.57 In addition, manual refinement of the 
obtained structure was performed by REFMAC558 and COOT59  based on the 2FO-FC and FO-FC electron 
density maps. Refinement of LmNMT-4, LmNMT-6 and HsNMT1-8x was done using phenix.refine from the 
PHENIX software suite, as well as COOT. The model geometry was validated through the RSCB Protein Data 
Bank Validate Service.60 The crystallographic data for all structures are listed in Table S 2. 
Enzyme activity and inhibition assay 
Enzyme activity and inhibition was determined with a fluorescence based assay41 on a Tecan M200 infinite 
pro or Tecan Spark with 380 nm excitation and 470 nm emission wavelength. The assay was performed 
with 8 nM NMT in 110 µL sodium phosphate buffer pH 7.8 containing 0.5 mM EDTA and 0.05% triton-X 
100 using GSNKSKPK-amidation (pp60src(2-9)) as substrate and the cofactor MyrCoA. 7-diethylamino-3-(4-
maleimidyphenyl)-4-methylcoumarin (CPM) was used as fluorescent dye for free CoA detection after 
enzymatic reaction. For substrate KM determination a 30 min continuous assay was performed at a 
saturation concentration of MyrCoA of 30 µM and substrate concentration of 1 to 32 µM and a CPM 
concentration of 20 µM. The KM was calculated from the slope of the initial 10 min of the reaction. For IC50 
determination substrate and MyrCoA concentration were 4 µM and CPM concentration was 8 µM. 
Inhibitors were tested at ten different concentrations varying from 0.1 nM to 500 µM depending on the 
inhibitor. In all assays, DMSO content was at 0.9%. The inhibition assay was run as an endpoint assay and 
stopped after 30 min with 60 µL 0.1 M sodium acetate buffer pH 4.5. All assays were performed at least in 
duplicates. Inhibition constants (Ki) for comparability between different NMTs and mutants were 
calculated from IC50 and KM values using the Cheng-Prusoff equation.61 
ITC 
All ITC experiments were performed with a MicroCal VP-ITC instrument at 20 °C using a buffer with 50 mM 
sodium phosphate at pH 7.5 containing 0.5 mM EDTA and 1 mM beta-mercaptoethanol. Enzyme 
concentration of 10 µM and inhibitor concentrations of 100 µM were used. MyrCoA was present at 40 µM 
for all titrations and the final DMSO content was at 0.5 % for compounds 1 and 5 and at 0.2 % for all other 
compounds tested. Affinity and binding thermodynamics of compound 5 binding to HsNMT1 were 
determined using a displacement experiment. For that purpose, compound 1 was titrated against HsNMT1 
in the presence of 40 µM compound 5. Kd and thermodynamic profile of the displaced compound 5 were 
calculated from the observed Kd and ΔH° from the displacement experiment and the standard experiment 
for the higher affinity ligand 1.62  
Molecular Dynamics Simulations  
MD simulations were set up using the crystal structures available at the time (Table S 5). For protein-ligand 
complexes where no crystal structure was available, docking poses generated using LeadIT-2.1.663 were 
used as starting points. For compounds 2, 4 and 6 the docking poses were later confirmed by 
crystallography for complexes with HsNMT1. For HsNMT1 which crystallized with two monomers in the 
asymmetric unit, chain A was used for MD simulations as biological assembly, except for 3IU1 where chain 
B was used because of missing residues in the A chain. Histidines were protonated at the epsilon nitrogen 
except for His12 in LmNMT which was modelled as positively charged and His219/298 (LmNMT/HsNMT1) 
which was modelled as delta protonated due to the observed hydrogen-bond interactions with 
neighboring residues. For simulations of mutant proteins the amino acids were exchanged using PyMOL.64 
The simulation systems were subsequently built within VMD 1.9.265 keeping all crystallographic water 
molecules. Parameters for MyrCoA and inhibitors were generated with the CGenFF webservice.66,67 
Parameters for the thioester moiety of the co-factor MyrCoA (which is lacking in CGenFF) were generated 
from QM-derived (HF/6-31G*) parameters for bond lengths, angles, dihedrals and charges calculated for 
S-ethyl thiopropionate with Gaussian0968 and fitted for compatibility with CHARMM using the force field 
toolkit (FFtk)69 within VMD. Due to an instable binding mode throughout the trajectory of complexes with 
compounds 1 and 2 (data not shown), these compounds’ angles and dihedrals were taken from MMFF94 
and adapted to compatibility with CHARMM using the SwissParam-webserver.70 The complexes were 
solvated in a TIP3P71 water box exceeding the complex structure by 10 Å. The solvated complexes were 
charge neutralized with sodium ions and minimized over 2,000 time steps with NAMD 2.1172 using the 
CHARMM36 force field.73,74 The minimized complexes were subsequently equilibrated with harmonic 
constraints applied to all non-water atoms and the systems were heated from 100 to 300 K over 500 ps. 
Constraints were gradually released over the following 500 ps in a constant-volume box. Periodic boundary 
conditions were applied to the systems. The production runs were carried out for 50 ns using constant 
pressure and temperature.75,76 Throughout equilibration and production the van der Waals cut-off was set 
to 14 Å and the particle mesh Ewald methodology for electrostatic interactions was applied. Time steps of 
2 fs were used in combination with rigid bond lengths and trajectories were written every ps. All 
simulations were performed on the graphic processing units of the high performance cluster “Mogon” at 
the Johannes Gutenberg University of Mainz.  
MD simulations were analyzed using VMD 1.9.2 and compatible scripts. Convergence of the simulations 
was checked using an RMSD-based approach.77 Order parameters S² were calculated as described 
previously using the isotropic reorientational eigenmode dynamics (iRED) approach78 in cpptraj.79 Water 
density maps and peaks were calculated with ccptraj79 from AmberTools17 as well.80 For quantitative 
analysis of hydration sites the SPAM approach45  was used within cpptraj. The bulk water thermodynamics 
were derived from a 10 ns MD simulation of a 40 Å * 40 Å * 40 Å pure water box using the TIP3P water 
model and the CHARMM36 force field. The calculated GSPAM for bulk water was -29.60 kcal/mol, HSPAM -
17.61 +/- 5.43 kcal/mol and -TSSPAM -11.98 kcal/mol. 
Virtual screening and docking 
A virtual small-molecule compound library was derived from the ZINC 15 database81,82 using the following 
filters: reactivity = "anodyne" (to exclude reactive molecules and PAINs),83 molecular weight (Mw ) > 300 
Da, log P -1 – +5, charge (0 – +1), availability (in stock or via agent) and "pH" (reference and neutral to 
obtain only relevant protonation states) were applied. This resulted in 5,835,796 protomers, which were 
additionally filtered using MOE 2015.1001.84 Molecules with the following properties were allowed to pass 
this additional filter step: Mw < 550 Da, H-bond acceptor count < 11, H-bond donor count < 6, number of 
rings 2-5, number of rotatable bonds < 11, aromatic atoms > 10 (corresponds to 2 or more aromatic rings) 
and exactly 1 basic atom. This resulted in 686,285 molecules. 
Conformers for the subsequent pharmacophore query were generated using Omega with default settings 
(OMEGA 2.5.1.4: OpenEye Scientific Software, Santa Fe, NM).85 The pharmacophore model contained the 
following features (Figure S 2): A hydrogen-bond acceptor to interact with the hydroxyl group of Ser330, 
adjacent to or part of an aromatic ring to interact with lipophilic residues (Phe88, Phe90, Phe232), an 
additional aromatic moiety to interact with Tyr217, and a basic center to interact with the C-terminal 
residue Leu421. Any atom at a similar position as C2 of the indole moiety of compound 5 was included to 
achieve selectivity for LmNMT over HsNMT1. 8,174 compounds passed this pharmacophore query.  
The remaining molecules were docked without any restraints using LeadIT-2.1.6.63 The docking strategy 
was validated by redocking of compounds 5, 6a and 7, which resulted in RMSD values between docked 
and crystallographically determined binding modes between 1.05 and 1.70 Å. The obtained poses were 
visually inspected and the 200 highest scoring molecules predicted to form crucial interactions (H-bond 
with Ser330, direct or indirect ionic interaction with the C-terminal Leu421, and placement of an aromatic 
moiety into the sub-pocket close to Tyr217) were rescored using the HYDE86 scoring function. After 
commercial availability check, compounds 9-14 (Table S 7), which had all crucial interactions and the best 
HYDE scores, were purchased from Chembridge/hit2lead or WuXi Apptec/LabNetwork). These compounds 
have not been flagged as pan assay interference compounds (PAINS). 
Supporting Information 
The following is supplied as Supporting information: 
- tables providing ITC data, data collection and refinement statistics, KM values for LmNMT, HsNMT1 
and their variants, backbone 1D-RMSD values and side-chain order parameters from MD 
simulations, calculated binding energies of W1 binding to various NMT variants, and structures 
and scores of tested compounds from the virtual screening  
- figures describing the interactions of Arg295 in HsNMT1 , the pharmacophore used for virtual 
screening and the binding modes of 6 and 6a 
- coordinates of the predicted binding modes of compounds 9- 11 
- Molecular Formula Strings 
Accession Codes 
The described structures have been deposited in the PDB with the following codes: HsNMT1-2: 6FZ3, 
HsNMT1-4, 6FZ5, HsNMT1-6, 6FZ2, HsNMT1-8x: 6F56, LmNMT-4: 6EU5, LmNMT-6: 6EWF. The authors will 
release the atomic coordinates and experimental data upon article publication.  
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